Literature DB >> 17202328

TCR activation eliminates glutamate receptor GluR3 from the cell surface of normal human T cells, via an autocrine/paracrine granzyme B-mediated proteolytic cleavage.

Yonatan Ganor1, Vivian I Teichberg, Mia Levite.   

Abstract

The majority of resting normal human T cells, like neuronal cells, express functional receptors for glutamate (the major excitatory neurotransmitter in the CNS) of the ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-receptor subtype 3 (GluR3). Glutamate by itself ( approximately 10 nM) activates key T cell functions, including adhesion to fibronectin and laminin and chemotactic migration toward CXCL12/stromal cell-derived factor 1. In this study, we found by GluR3-specific immunostaining, flow cytometry, and Western blots that GluR3 cell surface expression decreases dramatically following TCR activation of human T cells. CXCR4, VLA-4, and VLA-6 also decrease substantially, whereas CD147 increases as expected, after TCR activation. Media of TCR-activated cells "eliminates" intact GluR3 (but not CXCR4 and VLA-6) from the cell surface of resting T cells, suggesting GluR3 cleavage by a soluble factor. We found that this factor is granzyme B (GB), a serine protease released by TCR-activated cells, because the extent of GluR3 elimination correlated with the active GB levels, and because three highly specific GB inhibitors blocked GluR3 down-regulation. Media of TCR-activated cells, presumably containing cleaved GluR3B peptide (GluR3 aa 372-388), inhibited the specific binding of anti-GluR3B mAb to synthetic GluR3B peptide. In parallel to losing intact GluR3, TCR-activated cells lost glutamate-induced adhesion to laminin. Taken together, our study shows that "classical immunological" TCR activation, via autocrine/paracrine GB, down-regulates substantially the expression of specific neurotransmitter receptors. Accordingly, glutamate T cell neuroimmune interactions are influenced by the T cell activation state, and glutamate, via AMPA-GluR3, may activate only resting, but not TCR-activated, T cells. Finally, the cleavage and release to the extracellular milieu of the GluR3B peptide may in principle increase its antigenicity, and thus the production, of anti-self GluR3B autoantibodies, which activate and kill neurons, found in patients with various types of epilepsy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17202328     DOI: 10.4049/jimmunol.178.2.683

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  24 in total

Review 1.  Death by a thousand cuts: granzyme pathways of programmed cell death.

Authors:  Dipanjan Chowdhury; Judy Lieberman
Journal:  Annu Rev Immunol       Date:  2008       Impact factor: 28.527

2.  Nonapoptotic and extracellular activity of granzyme B mediates resistance to regulatory T cell (Treg) suppression by HLA-DR-CD25hiCD127lo Tregs in multiple sclerosis and in response to IL-6.

Authors:  Siddheshvar Bhela; Christine Kempsell; Monali Manohar; Margarita Dominguez-Villar; Russell Griffin; Pooja Bhatt; Pia Kivisakk-Webb; Robert Fuhlbrigge; Thomas Kupper; Howard Weiner; Clare Baecher-Allan
Journal:  J Immunol       Date:  2015-01-30       Impact factor: 5.422

Review 3.  Effector T Cells in Multiple Sclerosis.

Authors:  Belinda J Kaskow; Clare Baecher-Allan
Journal:  Cold Spring Harb Perspect Med       Date:  2018-04-02       Impact factor: 6.915

4.  Mouse T cells express a neurotransmitter-receptor signature that is quantitatively modulated in a subset- and activation-dependent manner.

Authors:  Kenneth M Rosenberg; Nevil J Singh
Journal:  Brain Behav Immun       Date:  2019-04-03       Impact factor: 7.217

Review 5.  The neurotransmitter glutamate and human T cells: glutamate receptors and glutamate-induced direct and potent effects on normal human T cells, cancerous human leukemia and lymphoma T cells, and autoimmune human T cells.

Authors:  Yonatan Ganor; Mia Levite
Journal:  J Neural Transm (Vienna)       Date:  2014-03-02       Impact factor: 3.575

6.  Granzyme B produced by human plasmacytoid dendritic cells suppresses T-cell expansion.

Authors:  Bernd Jahrsdörfer; Angelika Vollmer; Sue E Blackwell; Julia Maier; Kai Sontheimer; Thamara Beyer; Birgit Mandel; Oleg Lunov; Kyrylo Tron; G Ulrich Nienhaus; Thomas Simmet; Klaus-Michael Debatin; George J Weiner; Dorit Fabricius
Journal:  Blood       Date:  2009-12-03       Impact factor: 22.113

Review 7.  Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor's expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy.

Authors:  Mia Levite
Journal:  J Neural Transm (Vienna)       Date:  2014-08-01       Impact factor: 3.575

Review 8.  Diagnostic and pathogenic significance of glutamate receptor autoantibodies.

Authors:  David Pleasure
Journal:  Arch Neurol       Date:  2008-05

9.  Glutamate Receptor Interacting Protein 1 Regulates CD4(+) CTLA-4 Expression and Transplant Rejection.

Authors:  K L Modjeski; S C Levy; S K Ture; D J Field; G Shi; K Ko; Q Zhu; C N Morrell
Journal:  Am J Transplant       Date:  2016-02-25       Impact factor: 8.086

10.  Autoantibodies against opioid or glutamate receptors are associated with changes in morphine reward and physical dependence in mice.

Authors:  Francesca Capone; Walter Adriani; Maria Shumilina; Galina Izykenova; Oleg Granstrem; Svetlana Dambinova; Giovanni Laviola
Journal:  Psychopharmacology (Berl)       Date:  2008-02-12       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.